Get access

Intravenous zoledronate for postmenopausal osteoporosis

  • Protocol
  • Intervention

Authors

  • Ben-Hur Albergaria,

    Corresponding author
    1. Federal University of Espirito Santo, Osteoporosis Diagnosis and Research Center (CEDOES), Victoria, Espirito Santo, Brazil
    • Ben-Hur Albergaria, Osteoporosis Diagnosis and Research Center (CEDOES), Federal University of Espirito Santo, Joao da Silva Abreu 78- Praia do Canto, Victoria, Espirito Santo, 29055 450, Brazil. benhur.gaz@terra.com.br.

    Search for more papers by this author
  • Brenda Nazaré Gomes Silva,

    1. The Brazilian Cochrane Centre, São Paulo, São Paulo, Brazil
    Search for more papers by this author
  • Álvaro N Atallah,

    1. Universidade Federal de São Paulo / Escola Paulista de Medicina, Brazilian Cochrane Centre, São Paulo, SP, Brazil
    Search for more papers by this author
  • Virginia Fernandes Moça Trevisani

    1. Universidade Federal de São Paulo, Rheumatology/Internal Medicine and Therapeutics, São Paulo, São Paulo, Brazil
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the efficacy and safety of zoledronic acid therapy in the prevention and treatment of postmenopausal osteoporosis compared to placebo or active comparator (other bisphosphonates).